Correction: Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
=========================================================================================================================


Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. *J Immunother Cancer* 2022;10:e004693. doi:10.1136/jitc-2022-004693

In the section titled 'Induced pluripotent stem cell-derived NK cell therapies', The sentence 'For instance, CAR-NK cells derived from iPSCs targeting mesothelin showed strong in vivo responses in mouse A1847 ovarian cancer and outperformed PB-NK cell therapy' has had the phrase 'mouse A1847 ovarian cancer' updated to 'human A1847 ovarian cancer'.

*   © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

[http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).